

April 2, 2007  
Contact:  
Birgit Grund  
Fresenius AG  
Investor Relations  
Tel. ++49 - 6172 - 608 2485  
Fax ++49 - 6172 - 608 2488  
e-mail: [ir-fre@fresenius.de](mailto:ir-fre@fresenius.de)  
Internet: <http://www.fresenius-ag.com>

## Fresenius Investor News

### Fresenius ProServe completes the divestiture of Pharmaplan GmbH

Fresenius ProServe closed the announced divestiture of its subsidiary Pharmaplan GmbH to NNE A/S on March 31, 2007. All necessary antitrust approvals were received by NNE prior to the completion of the acquisition.

NNE is a wholly-owned subsidiary of Novo Nordisk A/S, Copenhagen, a pharmaceutical company with approximately 23,200 employees worldwide and annual sales of €5,194 million in 2006.

Pharmaplan provides consulting, engineering and qualification/validation services for the pharmaceutical industry worldwide. The sale of Pharmaplan is a further step by Fresenius ProServe to focus on its two core areas hospital operations (HELIOS Kliniken) and hospital engineering and services (VAMED).

\*\*\*

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.